Coeptis Therapeutics Holdings, Inc.

false 0001759186 0001759186 2026-04-24 2026-04-24 0001759186 us-gaap:CommonStockMember 2026-04-24 2026-04-24 0001759186 us-gaap:WarrantMember 2026-04-24 2026-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 24, 2026 _____________________ COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 105 Bradford Rd , Suite 420 Wexford , Pennsylvania 15090 (Address of principal executive offices) (Zip Code) 724 - 934-6467 (Registrant’s telephone number, including area code) ____________________________________________________________ (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Market Warrants, each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share COEPW Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure On April 24, 2026, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis”) issued a press release (the “Press Release”) announcing that it had completed its business combination with Z Squared Inc. (“Z Squared”) and that its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol “ZSQR” on Monday, April 27, 2026 (CUSIP: 98878K108). A copy of the Press Release is furnished as Exhibit 99.1 and incorporated herein by reference . The Press Release is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No . Description 99.1 Press Release, dated April 24, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: April 24, 2026 By: /s/ David Halabu David Halabu Chief Executive Officer 3